58 results on '"Ramji, Alnoor"'
Search Results
2. A global research priority agenda to advance public health responses to fatty liver disease
3. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries
4. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
5. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
6. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada
7. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
8. FRI-130 - Low HBV treatment uptake among Rwandan people with HIV and HCV co-infections: a cohort study from 2016 to 2019
9. WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series
10. WED-429 Hepatitis B virus care cascade in Rwanda: a population basedstudy
11. OS-058 Disparities in hepatocellular carcinoma survival among people with hepatitis B or hepatitis C virus infection in Canada
12. THU-207 - Ethnic disparity in mortality related to extrahepatic manifestations among people with chronic HCV infection: a large, linked administrative population-based study in British Columbia, Canada
13. WED-191 - Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network
14. WED-194 - Barriers to hepatitis B treatment from the patient’s perspectives: survey study by the Canadian hepatitis B network
15. FRI-151 - Strategies to eliminate hepatitis C virus infection in the Americas
16. FRI-125 - The impact of Covid-19 on hepatocellular carcinoma screening in British Columbia
17. SAT-432 - Velacur ACE outperforms CAP for liver fat quantification using MRI PDFF as the gold standard
18. SAT538 - Effect of hepatitis B virus treatment on all causes and liver-related death among patients living with HBV with cirrhosis in British Columbia in a population-based cohort study
19. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
20. GS-12-Ascending dose cohort study of inarigivir - A novel RIG I agonist in chronic HBV patients: Final results of the ACHIEVE trial
21. GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts
22. A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal on adenoma detection.
23. Deep Learning Based Shear Wave Detection and Segmentation Tool for Use in Point-of-Care for Chronic Liver Disease Assessments.
24. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
25. Sa1100 A New Standard: an Open Label Trial Examining the Effectiveness of Individualized Web Based Colonoscopy Preparation Instruction.
26. Sa1513 - Sustained Virological Response at 12 Weeks Following Direct-Acting Antiviral for Hepatitis C Infection is Associated with Reduction in Transient Elastography Scores.
27. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
28. Tu1028 Inter-Observer Reliability of the St. Paul's Endoscopy Comfort Scale (SPECS) for Upper Endoscopy.
29. Tu1047 Colonoscopy Report Completeness Improves at St. Paul's Hospital With the Implementation of a Dication Template.
30. Mo1125 Correlation of The St. Paul's Endoscopy Comfort Scale With Post-Procedure Pain Recollection Following Upper Endoscopy.
31. Sa1451 Development and Validation of the Saint Paul's Endoscopy Comfort Scale (Specs) for Colonoscopy.
32. Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection.
33. Su1009 Fibrosis Regression in Persons Treated for HBV Utilizing Transient Elastography (FibroScan).
34. Su1043 Predictors of Antiviral Therapy Initiation in Chronic Hepatitis C (HCV).
35. S1381: Prospective Blinded Evaluation of Factors Associated With Withdrawal Time During Colonoscopy: Endoscopist Is a Significant Factor.
36. THU425 - Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection.
37. AS091 - A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
38. SAT461 - Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials.
39. SAT447 - All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada.
40. THU448 - Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence.
41. THU437 - Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment.
42. AS070 - Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection.
43. Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment.
44. FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results.
45. FRI-170-Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada.
46. SAT-238-The impact of SVR from direct acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort.
47. THU399 - Alcohol use does not influence treatment uptake or outcomes in the DAA era.
48. THU184 - Hepatic steatosis predicts fibrosis in long-term methotrexate use.
49. LBP04 - Liver toxicity in the Phase 2 Catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients.
50. THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.